Literature DB >> 30593866

Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity.

Kerstin Hiesinger1, Karen M Wagner2, Bruce D Hammock2, Ewgenij Proschak1, Sung Hee Hwang3.   

Abstract

Over the last two decades polypharmacology has emerged as a new paradigm in drug discovery, even though developing drugs with high potency and selectivity toward a single biological target is still a major strategy. Often, targeting only a single enzyme or receptor shows lack of efficacy. High levels of inhibitor of a single target also can lead to adverse side effects. A second target may offer additive or synergistic effects to affecting the first target thereby reducing on- and off-target side effects. Therefore, drugs that inhibit multiple targets may offer a great potential for increased efficacy and reduced the adverse effects. In this review we summarize recent findings of rationally designed multitarget compounds that are aimed to improve efficacy and safety profiles compared to those that target a single enzyme or receptor. We focus on dual inhibitors/modulators that target the soluble epoxide hydrolase (sEH) as a common part of their design to take advantage of the beneficial effects of sEH inhibition.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dual inhibitors/modulators; Multitarget agents; Polypharmacology; Soluble epoxide hydrolase

Mesh:

Substances:

Year:  2018        PMID: 30593866      PMCID: PMC6345559          DOI: 10.1016/j.prostaglandins.2018.12.003

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  112 in total

Review 1.  Designed multiple ligands. An emerging drug discovery paradigm.

Authors:  Richard Morphy; Zoran Rankovic
Journal:  J Med Chem       Date:  2005-10-20       Impact factor: 7.446

2.  Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.

Authors:  Guodong Zhang; Dipak Panigrahy; Sung Hee Hwang; Jun Yang; Lisa M Mahakian; Hiromi I Wettersten; Jun-Yan Liu; Yanru Wang; Elizabeth S Ingham; Sarah Tam; Mark W Kieran; Robert H Weiss; Katherine W Ferrara; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

3.  Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

Authors:  Angelo Jayamanne; Ruth Greenwood; Vanessa A Mitchell; Sevda Aslan; Daniele Piomelli; Christopher W Vaughan
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 4.  Ligandomics: a paradigm shift in biological drug discovery.

Authors:  Wei Li; Iok-Hou Pang; Mario Thiego F Pacheco; Hong Tian
Journal:  Drug Discov Today       Date:  2018-01-08       Impact factor: 7.851

5.  Exploring the chemical space of multitarget ligands using aligned self-organizing maps.

Authors:  Janosch Achenbach; Franca-Maria Klingler; René Blöcher; Daniel Moser; Ann-Kathrin Häfner; Carmen B Rödl; Simon Kretschmer; Björn Krüger; Frank Löhr; Holger Stark; Bettina Hofmann; Dieter Steinhilber; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2013-10-23       Impact factor: 4.345

6.  Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids.

Authors:  Amy A Rand; Bogdan Barnych; Christophe Morisseau; Tomas Cajka; Kin Sing Stephen Lee; Dipak Panigrahy; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-10       Impact factor: 11.205

7.  Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.

Authors:  Darren Fegley; Silvana Gaetani; Andrea Duranti; Andrea Tontini; Marco Mor; Giorgio Tarzia; Daniele Piomelli
Journal:  J Pharmacol Exp Ther       Date:  2004-12-03       Impact factor: 4.030

8.  Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.

Authors:  Yosabeth Paredes; Frédéric Massicotte; Jean-Pierre Pelletier; Johanne Martel-Pelletier; Stefan Laufer; Daniel Lajeunesse
Journal:  Arthritis Rheum       Date:  2002-07

9.  Rapid purification of cytosolic epoxide hydrolase from normal and clofibrate-treated animals by affinity chromatography.

Authors:  G D Prestwich; B D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

10.  Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening.

Authors:  Veronika Temml; Ulrike Garscha; Erik Romp; Gregor Schubert; Jana Gerstmeier; Zsofia Kutil; Barbara Matuszczak; Birgit Waltenberger; Hermann Stuppner; Oliver Werz; Daniela Schuster
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

View more
  14 in total

1.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

2.  Multi-Target Drugs for Kidney Diseases.

Authors:  John D Imig; Daniel Merk; Eugen Proschak
Journal:  Kidney360       Date:  2021-08-02

Review 3.  Soluble Epoxide Hydrolase as a Therapeutic Target for Neuropsychiatric Disorders.

Authors:  Jiajing Shan; Kenji Hashimoto
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

4.  Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

Authors:  Kerstin Hiesinger; Annika Schott; Jan S Kramer; René Blöcher; Finja Witt; Sandra K Wittmann; Dieter Steinhilber; Denys Pogoryelov; Jana Gerstmeier; Oliver Werz; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2019-10-30       Impact factor: 4.345

Review 5.  Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis.

Authors:  Ryan D Jones; Jie Liao; Xin Tong; Dandan Xu; Leyu Sun; Haonan Li; Guang-Yu Yang
Journal:  Front Pharmacol       Date:  2019-06-25       Impact factor: 5.810

Review 6.  Oxidized Lipids in Persistent Pain States.

Authors:  Tabea Osthues; Marco Sisignano
Journal:  Front Pharmacol       Date:  2019-10-15       Impact factor: 5.810

7.  Colocalization of MID1IP1 and c-Myc is Critically Involved in Liver Cancer Growth via Regulation of Ribosomal Protein L5 and L11 and CNOT2.

Authors:  Ji Hoon Jung; Hyo-Jung Lee; Ju-Ha Kim; Deok Yong Sim; Eunji Im; Sinae Kim; Suhwan Chang; Sung-Hoon Kim
Journal:  Cells       Date:  2020-04-16       Impact factor: 6.600

Review 8.  Inhibition of the Soluble Epoxide Hydrolase as an Analgesic Strategy: A Review of Preclinical Evidence.

Authors:  Yuxin Wang; Karen M Wagner; Christophe Morisseau; Bruce D Hammock
Journal:  J Pain Res       Date:  2021-01-13       Impact factor: 3.133

9.  Fish Oil Improves Pathway-Oriented Profiling of Lipid Mediators for Maintaining Metabolic Homeostasis in Adipose Tissue of Prediabetic Rats.

Authors:  Gabriel Dasilva; Salomé Lois; Lucía Méndez; Bernat Miralles-Pérez; Marta Romeu; Sara Ramos-Romero; Josep L Torres; Isabel Medina
Journal:  Front Immunol       Date:  2021-04-21       Impact factor: 7.561

Review 10.  Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.

Authors:  Cheng-Peng Sun; Xin-Yue Zhang; Christophe Morisseau; Sung Hee Hwang; Zhan-Jun Zhang; Bruce D Hammock; Xiao-Chi Ma
Journal:  J Med Chem       Date:  2020-12-28       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.